CD44 Promotes Breast Cancer Metastasis through AKT-Mediated Downregulation of Nuclear FOXA2
Abstract
:1. Introduction
2. Materials and Methods
2.1. Human Specimens
2.2. Cell Culture
2.3. Transwell Migration and Invasion Assays
2.4. Western Blo
2.5. Immunohistochemistry
2.6. Flow Cytometry
2.7. Tumorsphere Formation Assay
2.8. Human Cancer Stem Cell Array
2.9. Gene Knockdown and Overexpression
2.10. Statistics
3. Results
3.1. CD44 Expression Was Higher in Metastatic Lymph Nodes and CD44 Knockdown Reduced Migration and Invasion Abilities of Breast Cancer Cells
3.2. FOXA2 Was Upregulated in CD44 Knockdown Cells
3.3. Inhibition of FOXA2 in CD44 Knockdown Cells Reversed Cell Phenotype from Epithelial to Mesenchymal
3.4. CD44 Leads to Multiple Drug Resistance in Breast Cancer Cells
3.5. FOXA2 Accumulates in the Nucleus in CD44low Breast Cancer Cells
3.6. AKT Activation Results in Cytoplasmic Translocation of FOXA2
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [Green Version]
- Medeiros, B.; Allan, A.L. Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives. Int. J. Mol. Sci. 2019, 20, 2272. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Turashvili, G.; Brogi, E. Tumor heterogeneity in breast cancer. Front. Med. 2017, 4, 227. [Google Scholar] [CrossRef] [Green Version]
- Xu, H.; Niu, M.; Yuan, X.; Wu, K.; Liu, A. CD44 as a tumor biomarker and therapeutic target. Exp. Hematol. Oncol. 2020, 9, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Al-Othman, N.; Alhendi, A.; Ihbaisha, M.; Barahmeh, M.; Alqaraleh, M.; Al-Momany, B.Z. Role of CD44 in breast cancer. Breast Dis. 2020, 39, 1–13. [Google Scholar] [CrossRef] [PubMed]
- Herishanu, Y.; Gibellini, F.; Njuguna, N.; Hazan-Halevy, I.; Keyvanfar, K.; Lee, E.; Wilson, W.; Wiestner, A. CD44 signaling via PI3K/AKT and MAPK/ERK pathways protects CLL cells from spontaneous and drug induced apoptosis through MCL-1. Leuk. Lymphoma 2011, 52, 1758. [Google Scholar] [CrossRef]
- Ponta, H.; Sherman, L.; Herrlich, P.A. CD44: From adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003, 4, 33–45. [Google Scholar] [CrossRef] [PubMed]
- Waugh, D.J.; McClatchey, A.; Montgomery, N.; McFarlane, S. Adhesion and penetration: Two sides of CD44 signal transduction cascades in the context of cancer cell metastasis. In Hyaluronan in Cancer Biology; Elsevier: Amsterdam, The Netherlands, 2009; pp. 109–125. [Google Scholar]
- Orian-Rousseau, V.; Chen, L.; Sleeman, J.P.; Herrlich, P.; Ponta, H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002, 16, 3074–3086. [Google Scholar] [CrossRef] [Green Version]
- Dalerba, P.; Dylla, S.J.; Park, I.-K.; Liu, R.; Wang, X.; Cho, R.W.; Hoey, T.; Gurney, A.; Huang, E.H.; Simeone, D.M. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104, 10158–10163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Santoyo-Ramos, P.; Likhatcheva, M.; García-Zepeda, E.A.; Castañeda-Patlán, M.C.; Robles-Flores, M. Hypoxia-inducible factors modulate the stemness and malignancy of colon cancer cells by playing opposite roles in canonical Wnt signaling. PLoS ONE 2014, 9, e112580. [Google Scholar] [CrossRef] [PubMed]
- Ouhtit, A.; Abd Elmageed, Z.Y.; Abdraboh, M.E.; Lioe, T.F.; Raj, M.H. In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am. J. Pathol. 2007, 171, 2033–2039. [Google Scholar] [CrossRef] [Green Version]
- Wu, K.; Ning, Z.; Zeng, J.; Fan, J.; Zhou, J.; Zhang, T.; Zhang, L.; Chen, Y.; Gao, Y.; Wang, B. Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial–mesenchymal transition and stemness. Cell. Signal. 2013, 25, 2625–2633. [Google Scholar] [CrossRef]
- Yu, D.; Shin, H.-S.; Lee, Y.S.; Lee, Y.C. miR-106b modulates cancer stem cell characteristics through TGF-β/Smad signaling in CD44-positive gastric cancer cells. Lab. Investig. 2014, 94, 1370–1381. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.-Y.; Vadhan, A.; Chen, P.-H.; Lee, Y.-L.; Chao, C.-Y.; Cheng, K.-H.; Chang, Y.-C.; Hu, S.C.-S.; Yuan, S.-S.F. CD44 Promotes Lung Cancer Cell Metastasis through ERK–ZEB1 Signaling. Cancers 2021, 13, 4057. [Google Scholar] [CrossRef] [PubMed]
- Luo, Z.; Wu, R.-R.; Lv, L.; Li, P.; Zhang, L.-Y.; Hao, Q.-L.; Li, W. Prognostic value of CD44 expression in non-small cell lung cancer: A systematic review. Int. J. Clin. Exp. Pathol. 2014, 7, 3632. [Google Scholar] [PubMed]
- Xie, G.; Yao, Q.; Liu, Y.; Du, S.; Liu, A.; Guo, Z.; Sun, A.; Ruan, J.; Chen, L.; Ye, C. IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int. J. Oncol. 2012, 40, 1171–1179. [Google Scholar] [PubMed] [Green Version]
- Uchino, M.; Kojima, H.; Imada, K.M.; Onoda, F.; Satofuka, H.; Utsugi, T.; Murakami, Y. Nuclear b-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells. BMC Cancer 2012, 10, 414. [Google Scholar] [CrossRef] [Green Version]
- Cho, Y.; Lee, H.-W.; Kang, H.-G.; Kim, H.-Y.; Kim, S.-J.; Chun, K.-H. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget 2015, 6, 8709. [Google Scholar] [CrossRef] [Green Version]
- Chang, S.J.; Ou-Yang, F.; Tu, H.P.; Lin, C.H.; Huang, S.H.; Kostoro, J.; Hou, M.F.; Chai, C.Y.; Kwan, A.L. Decreased expression of autophagy protein LC3 and sternness (CD44+/CD24-/low) indicate poor prognosis in triple-negative breast cancer. Hum. Pathol. 2016, 48, 48–55. [Google Scholar] [CrossRef]
- McFarlane, S.; Coulter, J.A.; Tibbits, P.; O’Grady, A.; McFarlane, C.; Montgomery, N.; Hill, A.; McCarthy, H.O.; Young, L.S.; Kay, E.W. CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget 2015, 6, 11465. [Google Scholar] [CrossRef]
- Xu, H.; Tian, Y.; Yuan, X.; Liu, Y.; Wu, H.; Liu, Q.; Wu, G.S.; Wu, K. Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. OncoTargets Ther. 2016, 9, 431. [Google Scholar]
- Montgomery, N.; Hill, A.; McFarlane, S.; Neisen, J.; O'Grady, A.; Conlon, S.; Jirstrom, K.; Kay, E.W.; Waugh, D.J. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res. 2012, 14, R84. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Z.; Yang, C.; Gao, W.; Chen, T.; Qian, T.; Hu, J.; Tan, Y. FOXA2 attenuates the epithelial to mesenchymal transition by regulating the transcription of E-cadherin and ZEB2 in human breast cancer. Cancer Lett. 2015, 361, 240–250. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Chen, T.; Guo, M.; Li, Y.; Zhang, Q.; Tan, G.; Yu, L.; Tan, Y. FOXA2-Interacting FOXP2 Prevents Epithelial-Mesenchymal Transition of Breast Cancer Cells by Stimulating E-Cadherin and PHF2 Transcription. Front. Oncol. 2021, 11, 239. [Google Scholar] [CrossRef] [PubMed]
- Friedman, J.; Kaestner, K.H. The Foxa family of transcription factors in development and metabolism. Cell Mol. Life Sci. 2006, 63, 2317–2328. [Google Scholar] [CrossRef] [PubMed]
- Tang, Y.; Shu, G.; Yuan, X.; Jing, N.; Song, J. FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers. Cell Res. 2011, 21, 316–326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Basseres, D.S.; D’Alò, F.; Yeap, B.Y.; Löwenberg, E.C.; Gonzalez, D.A.; Yasuda, H.; Dayaram, T.; Kocher, O.N.; Godleski, J.J.; Richards, W.G. Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer 2012, 77, 31–37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jin, S.; He, J.; Zhou, Y.; Wu, D.; Li, J.; Gao, W. LncRNA FTX activates FOXA2 expression to inhibit non–small-cell lung cancer proliferation and metastasis. J. Cell. Mol. Med. 2020, 24, 4839–4849. [Google Scholar] [CrossRef] [Green Version]
- Salem, M.; O’Brien, J.A.; Bernaudo, S.; Shawer, H.; Ye, G.; Brkić, J.; Amleh, A.; Vanderhyden, B.C.; Refky, B.; Yang, B.B. miR-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2–versican pathway. Cancer Res. 2018, 78, 4175–4190. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vorvis, C.; Hatziapostolou, M.; Mahurkar-Joshi, S.; Koutsioumpa, M.; Williams, J.; Donahue, T.R.; Poultsides, G.A.; Eibl, G.; Iliopoulos, D. Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer. Am. J. Physiol.-Gastrointest. Liver Physiol. 2016, 310, G1124–G1137. [Google Scholar] [CrossRef] [PubMed]
- Chand, V.; Pandey, A.; Kopanja, D.; Guzman, G.; Raychaudhuri, P. Opposing roles of the forkhead box factors FoxM1 and FoxA2 in liver cancer. Mol. Cancer Res. 2019, 17, 1063–1074. [Google Scholar] [CrossRef] [PubMed]
- Bow, Y.D.; Wang, Y.Y.; Chen, Y.K.; Su, C.W.; Hsu, C.W.; Xiao, L.Y.; Yuan, S.S.; Li, R.N. Silencing of FOXA2 decreases E-cadherin expression and is associated with lymph node metastasis in oral cancer. Oral Dis. 2020, 26, 756–765. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.-Y.; Chen, Y.-K.; Lo, S.; Chi, T.-C.; Chen, Y.-H.; Hu, S.C.-S.; Chen, Y.-W.; Jiang, S.S.; Tsai, F.-Y.; Liu, W. MRE11 promotes oral cancer progression through RUNX2/CXCR4/AKT/FOXA2 signaling in a nuclease-independent manner. Oncogene 2021, 40, 3510–3532. [Google Scholar] [CrossRef] [PubMed]
- Zhan, F.; Zhong, Y.; Qin, Y.; Li, L.; Wu, W.; Yao, M. SND1 facilitates the invasion and migration of cervical cancer cells by Smurf1-mediated degradation of FOXA2. Exp. Cell Res. 2020, 388, 111809. [Google Scholar] [CrossRef]
- Wang, B.; Liu, G.; Ding, L.; Zhao, J.; Lu, Y. FOXA2 promotes the proliferation, migration and invasion, and epithelial mesenchymal transition in colon cancer. Exp. Ther. Med. 2018, 16, 133–140. [Google Scholar] [CrossRef] [Green Version]
- Connelly, Z.M.; Jin, R.; Zhang, J.; Yang, S.; Cheng, S.; Shi, M.; Cates, J.M.; Shi, R.; DeGraff, D.J.; Nelson, P.S. FOXA2 promotes prostate cancer growth in the bone. Am. J. Transl. Res. 2020, 12, 5619. [Google Scholar]
- Zhang, J.; Zhang, Z.; Sun, J.; Ma, Q.; Zhao, W.; Chen, X.; Qiao, H. MiR-942 regulates the function of breast cancer cell by targeting FOXA2. Biosci. Rep. 2019, 39, BSR20192298. [Google Scholar] [CrossRef] [Green Version]
- Shi, W.; Wang, X.; Ruan, L.; Fu, J.; Liu, F.; Qu, J. MiR-200a promotes epithelial-mesenchymal transition of endometrial cancer cells by negatively regulating FOXA2 expression. Die Pharm.-Int. J. Pharm. Sci. 2017, 72, 694–699. [Google Scholar]
- Huang, J.Y.; Wang, Y.Y.; Lo, S.; Tseng, L.M.; Chen, D.R.; Wu, Y.C.; Hou, M.F.; Yuan, S.S.F. Visfatin Mediates Malignant Behaviors through Adipose-Derived Stem Cells Intermediary in Breast Cancer. Cancers 2020, 12, 18. [Google Scholar] [CrossRef] [Green Version]
- Hung, A.C.; Lo, S.; Hou, M.F.; Lee, Y.C.; Tsai, C.H.; Chen, Y.Y.; Liu, W.; Su, Y.H.; Lo, Y.H.; Wang, C.H.; et al. Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation. Clin. Cancer Res. 2016, 22, 4478–4490. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.Y.; Chen, H.D.; Lo, S.; Chen, Y.K.; Huang, Y.C.; Hu, S.C.; Hsieh, Y.C.; Hung, A.C.; Hou, M.F.; Yuan, S.F. Visfatin Enhances Breast Cancer Progression through CXCL1 Induction in Tumor-Associated Macrophages. Cancers 2020, 12, 3526. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.F.; Lee, Y.C.; Wang, Y.Y.; Wang, C.H.; Hou, M.F.; Yuan, S.S.F. YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells. Kaohsiung J. Med. Sci. 2019, 35, 408–416. [Google Scholar] [CrossRef] [PubMed]
- Negri, T.; Brich, S.; Bozzi, F.; Volpi, C.V.; Gualeni, A.V.; Stacchiotti, S.; De Cecco, L.; Canevari, S.; Gloghini, A.; Pilotti, S. New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs). Oncotarget 2017, 8, 32492–32504. [Google Scholar] [CrossRef] [PubMed]
- Cao, J.; Wang, X.; Wang, D.; Ma, R.; Li, X.; Feng, H.; Wang, J.; Liu, S.; Wang, L. PGC-1β cooperating with FOXA2 inhibits proliferation and migration of breast cancer cells. Cancer Cell Int. 2019, 19, 93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blom, N.; Gammeltoft, S.; Brunak, S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J. Mol. Biol. 1999, 294, 1351–1362. [Google Scholar] [CrossRef]
- Wong, Y.-H.; Lee, T.-Y.; Liang, H.-K.; Huang, C.-M.; Wang, T.-Y.; Yang, Y.-H.; Chu, C.-H.; Huang, H.-D.; Ko, M.-T.; Hwang, J.-K. KinasePhos 2.0: A web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns. Nucleic Acids Res. 2007, 35 (Suppl. 2), W588–W594. [Google Scholar] [CrossRef]
- Liu, S.; Cheng, C. Akt Signaling Is Sustained by a CD44 Splice Isoform–Mediated Positive Feedback Loop. Cancer Res. 2017, 77, 3791–3801. [Google Scholar] [CrossRef] [Green Version]
- Cho, S.H.; Park, Y.S.; Kim, H.J.; Kim, C.H.; Lim, S.W.; Huh, J.W.; Lee, J.H.; Kim, H.R. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int. J. Oncol. 2012, 41, 211–218. [Google Scholar]
- Gao, Y.; Ruan, B.; Liu, W.; Wang, J.; Yang, X.; Zhang, Z.; Li, X.; Duan, J.; Zhang, F.; Ding, R. Knockdown of CD44 inhibits the invasion and metastasis of hepatocellular carcinoma both in vitro and in vivo by reversing epithelial-mesenchymal transition. Oncotarget 2015, 6, 7828. [Google Scholar] [CrossRef] [Green Version]
- Marhaba, R.; Zöller, M. CD44 in cancer progression: Adhesion, migration and growth regulation. J. Mol. Histol. 2004, 35, 211–231. [Google Scholar] [CrossRef]
- Zhang, J.; He, X.; Wan, Y.; Zhang, H.; Tang, T.; Zhang, M.; Yu, S.; Zhao, W.; Chen, L. CD44 promotes hepatocellular carcinoma progression via upregulation of YAP. Exp. Hematol. Oncol. 2021, 10, 54. [Google Scholar] [CrossRef]
- Su, J.; Wu, S.; Wu, H.; Li, L.; Guo, T. CD44 is functionally crucial for driving lung cancer stem cells metastasis through Wnt/β-catenin-FoxM1-Twist signaling. Mol. Carcinog. 2016, 55, 1962–1973. [Google Scholar] [CrossRef] [PubMed]
- Bourguignon, L.Y.; Wong, G.; Earle, C.; Krueger, K.; Spevak, C.C. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J. Biol. Chem. 2010, 285, 36721–36735. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Spaeth, E.L.; Labaff, A.M.; Toole, B.P.; Klopp, A.; Andreeff, M.; Marini, F.C. Mesenchymal CD44 Expression Contributes to the Acquisition of an Activated Fibroblast Phenotype via TWIST Activation in the Tumor MicroenvironmentMSC Participation as Activated Fibroblasts Requires CD44. Cancer Res. 2013, 73, 5347–5359. [Google Scholar] [CrossRef] [PubMed]
- Xu, H.; Wu, K.; Tian, Y.; Liu, Q.; Han, N.; Yuan, X.; Zhang, L.; Wu, G.S.; Wu, K. CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. Int. J. Oncol. 2016, 49, 1343–1350. [Google Scholar] [CrossRef] [Green Version]
- Ryu, D.; Ryoo, I.-g.; Kwak, M.-K. Overexpression of CD44 standard isoform upregulates HIF-1α signaling in hypoxic breast cancer cells. Biomol. Ther. 2018, 26, 487. [Google Scholar] [CrossRef]
- Wang, J.; Zhu, C.-P.; Hu, P.-F.; Qian, H.; Ning, B.-F.; Zhang, Q.; Chen, F.; Liu, J.; Shi, B.; Zhang, X. FOXA2 suppresses the metastasis of hepatocellular carcinoma partially through matrix metalloproteinase-9 inhibition. Carcinogenesis 2014, 35, 2576–2583. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, C.-P.; Wang, J.; Shi, B.; Hu, P.-F.; Ning, B.-F.; Zhang, Q.; Chen, F.; Chen, W.-S.; Zhang, X.; Xie, W.-F. The transcription factor FOXA2 suppresses gastric tumorigenesis in vitro and in vivo. Dig. Dis. Sci. 2015, 60, 109–117. [Google Scholar] [CrossRef] [PubMed]
- Li, C.M.-C.; Gocheva, V.; Oudin, M.J.; Bhutkar, A.; Wang, S.Y.; Date, S.R.; Ng, S.R.; Whittaker, C.A.; Bronson, R.T.; Snyder, E.L. Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes Dev. 2015, 29, 1850–1862. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perez-Balaguer, A.; Ortiz-Martínez, F.; García-Martínez, A.; Pomares-Navarro, C.; Lerma, E.; Peiró, G. FOXA2 mRNA expression is associated with relapse in patients with triple-negative/basal-like breast carcinoma. Breast Cancer Res. Treat. 2015, 153, 465–474. [Google Scholar] [CrossRef] [PubMed]
- Wolfrum, C. From the Cover: Insulin regulates the activity of forkhead transcription factor Hnf-3/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc. Natl. Acad. Sci. USA 2003, 100, 11624–11629. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Choi, W.; Choe, S.; Lau, G.W. Inactivation of FOXA2 by respiratory bacterial pathogens and dysregulation of pulmonary mucus homeostasis. Front. Immunol. 2020, 11, 515. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vadhan, A.; Hou, M.-F.; Vijayaraghavan, P.; Wu, Y.-C.; Hu, S.C.-S.; Wang, Y.-M.; Cheng, T.-L.; Wang, Y.-Y.; Yuan, S.-S.F. CD44 Promotes Breast Cancer Metastasis through AKT-Mediated Downregulation of Nuclear FOXA2. Biomedicines 2022, 10, 2488. https://doi.org/10.3390/biomedicines10102488
Vadhan A, Hou M-F, Vijayaraghavan P, Wu Y-C, Hu SC-S, Wang Y-M, Cheng T-L, Wang Y-Y, Yuan S-SF. CD44 Promotes Breast Cancer Metastasis through AKT-Mediated Downregulation of Nuclear FOXA2. Biomedicines. 2022; 10(10):2488. https://doi.org/10.3390/biomedicines10102488
Chicago/Turabian StyleVadhan, Anupama, Ming-Feng Hou, Priya Vijayaraghavan, Yi-Chia Wu, Stephen Chu-Sung Hu, Yun-Ming Wang, Tian-Lu Cheng, Yen-Yun Wang, and Shyng-Shiou F. Yuan. 2022. "CD44 Promotes Breast Cancer Metastasis through AKT-Mediated Downregulation of Nuclear FOXA2" Biomedicines 10, no. 10: 2488. https://doi.org/10.3390/biomedicines10102488